We are live on
!
Find out more
PA
PharVision Advisers Portfolio holdings
AUM
$9.86M
1-Year Est. Return
9.93%
This Fund
S&P 500
This Quarter
Est. Return
+0.93%
1 Year Est. Return
+9.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
+$19.8M
(+11%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
11.78%
Top 10 Holdings %
Top 10 Hldgs %
3.45%
Holding
1,063
New
409
Increased
141
Reduced
117
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delek US
DK
|
+$871K |
| 2 |
Broadcom
AVGO
|
+$691K |
| 3 |
Agilent Technologies
A
|
+$650K |
| 4 |
Telos
TLS
|
+$640K |
| 5 |
Pagaya Technologies
PGY
|
+$627K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Array Technologies
ARRY
|
+$730K |
| 2 |
Vertiv
VRT
|
+$639K |
| 3 |
Zevra Therapeutics
ZVRA
|
+$635K |
| 4 |
BOW
Bowhead Specialty Holdings
BOW
|
+$608K |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$581K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Industrials | 15.13% |
| 3 | Financials | 12.4% |
| 4 | Consumer Discretionary | 11.79% |
| 5 | Healthcare | 11.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Avient
AVNT
$3.41B
| – | – |
-7,278
| Closed | -$240K |
|
702
Avery Dennison
AVY
$12.9B
| – | – |
-1,540
| Closed | -$250K |
|
703
Acuity Brands
AYI
$10.3B
| – | – |
-757
| Closed | -$261K |
|
704
AZZ Inc
AZZ
$4.41B
| – | – |
-2,204
| Closed | -$241K |
|
705
Boeing
BA
$175B
| – | – |
-1,509
| Closed | -$326K |
|
706
Credicorp
BAP
$30.9B
| – | – |
-1,045
| Closed | -$278K |
|
707
Atlanta Braves Holdings Series A
BATRA
$3.53B
| – | – |
-9,024
| Closed | -$410K |
|
708
Atlanta Braves Holdings Series B
BATRK
$3.27B
| – | – |
-8,360
| Closed | -$348K |
|
709
Barings BDC
BBDC
$885M
| – | – |
-11,991
| Closed | -$105K |
|
710
Bain Capital Specialty
BCSF
$833M
| – | – |
-10,566
| Closed | -$151K |
|
711
Bread Financial
BFH
$4.36B
| – | – |
-5,398
| Closed | -$301K |
|
712
Birkenstock
BIRK
$7.7B
| – | – |
-5,929
| Closed | -$268K |
|
713
Buckle
BKE
$2.35B
| – | – |
-6,292
| Closed | -$369K |
|
714
BioLife Solutions
BLFS
$1.56B
| – | – |
-12,389
| Closed | -$316K |
|
715
Blackbaud
BLKB
$1.65B
| – | – |
-4,341
| Closed | -$279K |
|
716
Barnes & Noble Education
BNED
$451M
| – | – |
-11,471
| Closed | -$114K |
|
717
Scotiabank
BNS
$108B
| – | – |
-3,241
| Closed | -$210K |
|
718
Broadridge
BR
$18.3B
| – | – |
-959
| Closed | -$228K |
|
|
BRY
719
DELISTED
Berry Corp
BRY
| – | – |
-39,511
| Closed | -$149K |
|
720
Bioventus
BVS
$895M
| – | – |
-15,302
| Closed | -$102K |
|
721
Byrna Technologies
BYRN
$90.1M
| – | – |
-18,913
| Closed | -$419K |
|
722
Cable One
CABO
$249M
| – | – |
-1,409
| Closed | -$249K |
|
723
Maplebear
CART
$10.7B
| – | – |
-6,468
| Closed | -$238K |
|
724
Capital City Bank Group
CCBG
$904M
| – | – |
-5,934
| Closed | -$248K |
|
725
Coeur Mining
CDE
$15.4B
| – | – |
-14,546
| Closed | -$273K |
|
Similar funds
BS
RG
MP
CCM
DFA
CCP
FRT
VH
PharVision Advisers's Q4 2025 Portfolio in Review
As of Q4 2025, PharVision Advisers held 1,063 positions worth $198M, up 11% from $178M the previous quarter. Its ten largest holdings account for 3.5% of the portfolio.
PharVision Advisers deployed $23.3M of net new capital in Q4 2025, opening 409 new positions and adding to 141 existing holdings. Its largest new stake was Delek US: 24,407 shares worth $724K.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Wayfair, an estimated $510K trimmed.
- PharVision Advisers's largest Q4 2025 buy was Delek US: 24,407 shares worth $724K.
- PharVision Advisers added most to NIO in Q4 2025, an estimated $557K increase.
- PharVision Advisers's biggest Q4 2025 reduction was Wayfair, cutting an estimated $510K.
- PharVision Advisers fully exited Array Technologies in Q4 2025, selling an estimated $730K.
- PharVision Advisers's ten largest holdings make up 3.5% of its $198M portfolio in Q4 2025.
- PharVision Advisers opened 409 new positions and closed 396 in Q4 2025.
- PharVision Advisers's portfolio value rose 11% quarter-over-quarter to $198M.
Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.